What do pri mary care pa tients think about ge neric drugs?
Introduction
In Eu ro pean coun tries as well as in the United States, ex pen di ture on drugs is con tin uously ris ing [Heffler et al. 2003 , Olson-Garewal 2001 . In Ger many, costs for ambulatory pre scrip tions ex ceeded 24 bil lion Euro in 2003 and this is a re cord num ber in both ab solute and rel a tive terms [Schwabe 2004 ]. Patients could save about 10 -30% by pur chasing ge neric drugs as op posed to brand-name drugs [Liberman and Rubinstein 2002] . German statu tory health in sur an ces could save another 1.5 bil lion Euro if the po ten tial of ge neric pre scrib ing was ex ploited to the full [Nink and Schröder 2004] .
By def i ni tion, generics are chem i cally identical to their brand named coun ter parts and can be mar keted when pat ents and other ex clu sive mar ket ing rights on brand-name drugs ex pire [Bae 1997] . The ma jor ar gu ment in fa vor of ge neric sub sti tu tion has al ways been cost con tain ment [Keith et al. 1998 ]. A drug ex isting as a ge neric may be pre scribed us ing the brand name of the prod uct and then be sub stituted by the ge neric by the phar ma cist. Al terna tively, it may be pre scribed us ing the In terna tional Non-pro pri etary Name (INN) of the drug, or the pro pri etary name of the ge neric drug ("brand-name ge neric") as fre quently done in Ger many Cline 2002, Schwabe 2004] . At the time of the sur vey, the cost of a pre scribed drug whether generic or oth er wise, was re funded in most instances by the stat u tory health in sur ance body ex cept, of cour se, when there was a fixed charge for the pa tient.
To day, in con trast to the sit u a tion in the past when prob lems of subtherapeutic lev els and/or some ad verse ef fects due to vari a tions in bioequivalence of a small num ber of generic drugs have been doc u mented [Gleiter and Gundert-Remy 1994, Meredith 1996] , the drug ap proval pro cess now has re quired bio equiv alence as well as equiv a lent high stan dards in qual ity and safety in the case of ge neric drugs [Gleiter et al. 1998 , Welage et al. 2001 .
Sev eral rea sons have been dis cussed as to why the eco nomic po ten tial of ge neric prescrib ing, i.e. the cost-ef fec tive ness of drug ther apy, is not fully re al ized [Ascione et al. 2001 , Lemye 2000 , McGettigan et al. 1997 , Mott and Cline 2002 , Suh 1999 . There is one set of rea sons that re fers to doc tor-re lated factors, es pe cially mis con cep tions about ge neric prod ucts and ge neric sub sti tu tion [Avery et al. 2000 , Banahan and Kolassa 1997 , Hellerstein 1998 ]. There is ev i dence that pa tient pref er ences can also be a bar rier to in creased ge neric pre scrib ing [Mott and Kreling 1998 ]. Pa tients may per ceive brand-name prod ucts as be ing of higher qual ity com pared to generic prod ucts. In one study in a Brit ish general prac tice, 46% of the pa tients ques tioned stated that they were dis sat is fied when confronted with a drug change to a ge neric prescrip tion [Dowell et al. 1995] . How ever, accord ing to a study in New Jer sey [McGettigan et al. 1997] , nearly all pa tients agreed to use a ge neric sub sti tute if the doc tor ap proved of such a sub sti tu tion.
The aim of this study was to ex am ine in more de tail the at ti tude of pa tients to wards ge neric drugs and ge neric sub sti tu tion of formerly orig i nal prod ucts. A spe cial fo cus was on pa tient sat is fac tion with the in for ma tion on generic drugs and sub sti tu tion pro vided by the gen eral prac ti tio ner (GP), since this may be an im por tant fac tor in the pre scrib ing and acceptance of ge neric drugs. The study was designed for a pri mary care set ting, be cause GPs is sue the larg est num ber of pre scrip tions in the out pa tient set ting.
Methods
This pa tient sur vey was em bed ded in a larger in ter ven tion study, de signed as a random ized, con trolled trial. GPs as signed to the "in ter ven tion arm" of the study were informed about their ac tual ge neric po ten tial and each GP was given a small book let with tips to ease com mu ni ca tion with pa tients when talk ing about ge neric sub sti tu tion. The aim of the in ter ven tion was to change the doctor's pre scrib ing be hav ior. GPs in the in terven tion arm should better re al ize the economic po ten tial of ge neric pre scrib ing, com pared to the GPs in the "con trol arm". In this pa per, we re port the re sults of the pa tient sur vey in the prac tices of the con trol arm. The study was ap proved by the Ethics Committee of the University of Göttingen.
Participants
A to tal of 46 ran domly se lected prac tices were con tacted in de fined re gions of three Ger man fed eral states (con trol arm of the study). The re cep tion ists in the par tic i pat ing prac tices were in structed to recruite con sec utive pa tients dur ing a de fined week. Af ter com plet ing a ques tion naire on the use of generic drugs, the pa tients could ei ther de posit the ques tion naire in a box lo cated at the re ception or send their ques tion naire in a stamped en ve lope to our de part ment. An swers were not dis closed to the prac tice staff.
The questionnaire
The ques tion naire con sisted of 16 closed ques tions. Af ter giv ing a short def i ni tion of ge neric drugs based on a well-known med icine (Bayer As pi rin as brand name and ASS as ge neric prep a ra tion), the pa tients were asked whether they had heard about this differ ence be fore. Fur ther ques tions fo cused on a gen eral as sess ment of generics, in con trast to brand-name drugs. A few ques tions re ferred to ex pe ri ence, if any, with ge neric drugs or generic sub sti tu tion of brand-name drugs. Be fore elic it ing some de mo graphic data, pa tients were asked whether they felt ap propriately informed about ge neric drugs and sub sti tu tion by their doc tor. A pre lim i nary ver sion of the ques tion naire was pi loted in 28 prac tices in a sep a rate re gion of North Ger many [Detlefsen et al. 2001] .
Analysis
To an a lyze the as so ci a tion be tween at titudes to wards ge neric drugs (re sponse variable) and ex pe ri ence with ge neric sub sti tution, de gree of in for ma tion, qual ity of the phy si cian-pa tient re la tion ship, acute versus chro nic dis ease, age, sex and ed u ca tion (explan a tory vari ables), we per formed mul ti ple lo gis tic re gres sions. Back ward elim i na tion was ap plied to se lect im por tant vari ables (level for elim i na tion: p = 0.05). We cal culated the odds ra tios (ORs) with the cor respond ing 95% con fi dence intervals (CIs) as measures of effect [SAS Institute 1999] .
About the qual ity of their doc tor's in forma tion on ge neric drugs and sub sti tu tion, 52 pa tients did not an swer the ques tions. Since miss ing data in these cases seem to rep re sent dis sat is fac tion with the doc tors' performance, we treated these 52 an swers as ex pres sions of dis sat is fac tion with their doc tor's in for mation. For lo gis tic re gres sion anal y sis, these an swers were coded as 0, in con trast to those pa tients who char ac ter ized their doc tor's infor ma tion as (very) good (= 1).
Results
Of 46 gen eral prac tices ad dressed, 31 partic i pated in this study. The main rea sons for not par tic i pat ing were "no in ter est" and the fear that the study would be time-con sum ing. Most prac tices (66%) were solo prac tices, all doc tors were vo ca tion ally trained GPs.
Ac cord ing to the study pro to col, 50 consec u tive pa tients per prac tice had to be addressed. Re cep tion ists were suc cess ful in recruit ing a to tal of 804 pa tients. Es pe cially be cause of time pres sure, it was dif fi cult for the re cep tion ists in some prac tices to ad dress this pre de ter mined num ber of peo ple dur ing the reg u lar con sul ta tion hours. Con sid er ing the study pro to col (i.e. ad dress ing a to tal of 50 pa tients) as cri te rion, the re sponse rate was 51.9%, con sid er ing the re cep tion ists' re port of how many pa tients they addressed (n = 1,268), the response rate was 63.4%.
Knowledge of generic drugs
Af ter pro vid ing the par tic i pants with a short def i ni tion of ge neric drugs, 63% (509/804) stated that they had al ready heard of the difHimmel, Simmenroth-Nayda, Niebling et al.
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Ta ble 1. Fac tors sig nif i cantly as so ci ated with re spon dents' opin ion that in ex pen sive drugs are of in fe rior qual ity*. * the fol low ing vari ables were in cluded in the logistic regression anal y sis: age, sex, dis ease (acute vs. chronic), ed u ca tion, num ber of drugs, doc tor-pa tient re la tion ship, knowl edge of dif fer ence be tween brand-name and ge neric drugs, ex pe ri ence of ge neric sub sti tu tion, costs as is sue in the doc tor-pa tient rela tion, cost sav ings in healthcare as ad di tional bur den for pa tients; se lec tion: back ward; ** "Prev a lence" re fers to the rate of pa tients in the given cat e gory who be lieved that in ex pen sive drugs are of in fe rior qual ity (e.g., 53.2% of pa tients older than 60 years). This fig ure can be com pared to the over all rate of pa tients who deemed in ex pen sive drugs of in fe rior qual ity (36.7%). *** com pared to pa tients be tween 18 and 40 years, mid dle-aged pa tients did not dif fer in their opin ion from youn ger ones. The anal y sis is based on n = 754 pa tients, 50 pa tients were ex cluded due to miss ing vari ables in the response or ex plan a tory vari ables.
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fer ence be tween brand-name drugs and gener ics be fore, most of them in the me dia (65%) and/or from their doc tor (52%). As ex pected, ed u ca tion had some influence on the knowl edge of the dif fer ence between ge neric and brand-name prod ucts. About three quar ters (303/406) of the pati ents with a formal ed u ca tion of 10 years or more re ported know ing the dif fer ence, where as only 52% (206/398) with less ed u ca tion did so.
General attitudes towards generic drugs
A con sid er able frac tion (36.7%, 295/804) of the to tal sam ple of re spon dents con sid ered in ex pen sive drugs to be in fe rior to, or dif ferent from, brand-name prod ucts. This at ti tude was more fre quent among those who felt that ge neric pre scrib ing was "in vented" to solve the fi nan cial cri sis in the Ger man health insur ance sys tem at their ex pense (OR: 6.2; 95% CI: 4.0 -9.8) and those who did not want to con sider eco nomic is sues dur ing the consul ta tion. A neg a tive view on ge neric drugs was also more fre quently ex pressed by older peo ple and, in de pend ently, chron i cally ill patients. Ex pe ri ence with ge neric drugs and/or sub sti tu tion as well as a higher ed u ca tion were a bar rier to wards neg a tive at ti tudes (Table 1) .
Assessment of prescribed generic drugs
Of the re spon dents, 42% were con scious of some ex pe ri ence with ge neric drugs and nearly 30% (222/804) re mem bered that their doc tor had changed a for mer pre scrip tion of a brand-name drug to a ge neric prod uct; 32 patients an swered sev eral ques tions about their ex pe ri ence with ge neric sub sti tu tion al though they were not amongst the 222 pa tients who re mem bered that their doc tor had sub sti tuted one or more brand-name drugs. Per haps these pa tients ex pe ri enced a ge neric sub sti tu tion in an other prac tice or at a phar macy but since the aim of the study was, be sides oth ers, to detect as so ci a tions be tween the doc tor's perfor mance and the pa tient's at ti tudes to wards ge neric sub sti tu tion, we excluded the 32 patients from further analyses.
More than half of these pa tients who remem bered a sub sti tu tion of a for mer brandname drug (112/222) had been skep ti cal about this sub sti tu tion, on prin ci ple or, at least, at the be gin ning. Fig ure 1 sum ma rizes the pa tients' re ported ex pe ri ence with the sub sti tu tion. Nearly 30% were not sat is fied with the in for ma tion given by their doc tor. About one in three pa tients had to be come accus tomed to a dif fer ent color or shape of the sub sti tuted drug. There were 12% of pa tients (26/213) that re ported a poorer ther a peu tic effect of the ge neric drug, com pared to the former brand-name prep a ra tion.
Peo ple who had been skep ti cal when first con fronted with a ge neric sub sti tu tion were more fre quently among those who did not feel well-in formed about this sub sti tu tion by their doc tor (OR: 2.7; 95% CI: 1.2 -5.9) and who had to be come ac cus tomed to the new shape and/or form of the sub sti tuted drug (Table 2). Pre scrip tion of two or more drugs was also as so ci ated with skep ti cism about ge neric sub sti tu tion. Most im por tant, there was a strong as so ci a tion be tween skep ti cism on generic sub sti tu tion and the opin ion that lowcost drugs are in fe rior to or dif fer ent than brand-name products (OR: 4.5; 95% CI: 2.0 -10.4). 
Discussion

Summary of main findings
Al though the ma jor ity of pa tients in this study seemed to be fa mil iar with the term "generic drug", more than one third of the respon dents ex pressed gen er ally neg a tive feelings to wards generics with re gard to their qual ity and ef fi cacy. Those who had been skep tical when first con fronted with a ge neric sub sti tu tion were more fre quently among those who con sid ered in ex pen sive drugs to be in fe rior and were not sat is fied with the doctor's in for ma tion on sub sti tu tion. Only a small frac tion of those pa tients who had, or re mem bered, some ex pe ri ence with ge neric drugs were not sat is fied with the ther a peu tic ben e fit from the drug.
Strengths and limitations
In ad di tion to pre vi ous stud ies [Avery et al. 2000 , Pedulka et al. 1989 ], we com pared pa tient at ti tudes to wards drugs with the (perceived) qual ity of the doc tor's in for ma tion on ge neric drugs and sub sti tu tion. Al though this study in cluded more prac tices and more patients than pre vi ous sur veys, a sam pling bias may have oc curred. Doc tors with low in ter est in pharmacotherapy and/or low rates of generic pre scrib ing may be underrepresented, the prac tice re cep tion ists may have more frequently ad dressed those pa tients who are easier to han dle and more in ter ested in health top ics. In this case, the study un der es ti mates the fre quency of critical attitudes towards generic drugs.
The doc tor's in for ma tion be hav ior was only as sessed from a pa tient's point of view. We do not ex actly know whether a neg a tive as sess ment of ge neric drugs re sults from being in ad e quately in formed or whether ad equate in for ma tion was neg a tively per ceived by a very crit i cal or skeptic patient.
Any sur vey of ge neric drugs has to consider whether pa tients know what the term "ge neric" means. In a phar macy-based study in the Chi cago area, nearly all re spon dents were fa mil iar with this term [Pedulka et al. 1989] . The rate in our study was 63%. One rea son may be that the pub lic dis cus sion about cost con tain ment by use of ge neric drugs started in Ger many much later than in the United States where most pa tients need to pay for their drugs them selves so that con sum ers are also more price-sen si tive. An other rea son for this dif fer ence may be that the re spondents in our study first re ceived a def i ni tion of ge neric drugs so that it was eas ier for them to re port a knowl edge gap. Nevertheless, giv ing Himmel, Simmenroth-Nayda, Niebling et al.
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Ta ble 2. Fac tors sig nif i cantly as so ci ated with skep ti cism to wards ge neric sub sti tu tion*.
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Sig nif i cant at ti tudes/fac tors Prev a lence** Ad justed con fi dence (%) odds ra tio in ter val p
In ex pen sive drugs deemed to be in fe rior 80.0 4.5 2.0 -10.4 0.0004 Prob lems to be come ac cus tomed to shape/form of the drug 71.7 2.8 1.3 -6.0 0.0085 Pre scrip tion of two drugs or more 47.1 2.5 1.2 -5.0 0.0106 Not sat is fied with doc tor's in for ma tion on sub sti tu tion 70.6 2.7 1.2 -5.9 0.0125 Ed u ca tion ≤ 9 years 61.0 2.1 1.1 -4.2 0.0270 * the fol low ing vari ables were in cluded in the lo gis tic re gres sion analysis: age, sex, dis ease (acute vs. chronic), ed u ca tion, num ber of drugs, doc tor-pa tient re la tion ship, knowl edge of dif fer ence be tween brand name and generic drugs, ex pe ri ence of ge neric sub sti tu tion, costs as is sue in the doc tor-pa tient re la tionship, cost sav ings in health care as an ad di tional bur den for pa tients, rel e vance of the price of a drug; se lec tion: back ward. The analy sis is based on n = 186 pa tients, 32 patients were ex cluded due to miss ing vari ables in the re sponse or ex plana tory vari ables. ** "Prev a lence" re fers to the rate of pa tients in the given cat e gory who were skeptic to wards ge neric sub stitu tion (e.g., 71.7% of pa tients who had to be come ac cus tomed to shape/form of the drug). This fig ure can be com pared to the over all rate of pa tients who wee skep tic to wards ge neric sub sti tu tion (50.5%).
all re spon dents a uni form def i ni tion of generic drugs may have pre vented an in for mation bias and thus con trib uted to the va lid ity of the study.
Implications of findings
Knowl edge of pa tients' at ti tudes to wards ge neric drugs and ex perience with ge neric drugs and ge neric sub sti tu tion, may be cru cial be cause neg a tive at ti tudes might re sult in a larger num ber of pre scrip tions, more prac tice vis its and emer gency room con sul ta tions and ad di tional hos pi tal iza tions as an HMO study sug gested [Horn et al. 1996, Kravitz and Romano 1996] . Many patients in our studywith and with out ex pe ri ence in ge neric substi tu tion -were skep ti cal about ge neric prepa ra tions, due to their prej u dice that in ex pensive drugs "must" be of in fe rior qual ity. This prej u dice seems to mir ror what Sara Fritz from the St. Pe ters burg Times called brandname fe tish, en cour aged by the drug man ufac tur ers' in ten sive con sumer ad ver tis ing in the US.
The prej u dice against ge neric drugs may be strength ened by moral haz ard [Lundin 2000 ]: pa tients as well as phy si cians do not have the in cen tive to in vest in low-cost treatment as long as in sur ance com pa nies pay the costs of pre scrip tions, re gard less of their generic or brand-name sta tus. In many countries, the mar ginal cost of treat ment, as econ omists put it, do not have to be cov ered by the pa tient in full in sur ance [de Joncheere et al. 2002 , Lundin 2000 . Our study seems to reflect this moral haz ard in two in stances: in that many pa tients' dis like talk ing about cost with their doc tor, and in their feel ing that generic pre scrip tions are a strat egy to reduce cost at the expense of patients.
In a study based on pre scrip tions in a US Mid west ern com mu nity [Mott and Kreling 1998 ], ge neric sub sti tu tion oc curred sig nif icantly more of ten for acute than for chronic con di tions. In our study, pa tients with chronic dis eases more of ten showed a neg a tive at ti tude to wards ge neric drugs, con firm ing as sump tions from dif fer ent au thors that chron i cally ill pa tients per ceive the con sequences and risks of ge neric sub sti tu tion as more se ri ous and have more fear of health loss [Ganther and Kreling 2000, Pedulka et al. 1989] . From an eco nomic point of view, par tic u larly in chronic pa tients, a sub sti tution is likely to have a re mark able ef fect in cost sav ing -at least for the stat u tory health in sur an ces. From a pri mary care point of view, it will be more dif fi cult for doc tors to per suade these pa tients to ac cept a ge neric sub sti tu tion with out first talk ing to them about their aver sion of tak ing generics for their dis or der [Pedulka et al. 1989] . The same will be true in older pa tients and in those who reg u larly take sev eral drugs. These per sons, too, may have gone through sev eral drug changes and may ex pe ri ence fur ther drug changes as a threat to their health so that com mu ni ca tion about their fears is es sen tial but time-con sum ing.
Be tween 12% and 13% of the pa tients in our study hav ing some ex pe ri ence of ge neric sub sti tu tion re ported a lower ef fi cacy or side ef fects. So did 20% or 26% of pa tients who felt very un happy or slightly un happy, re spectively, in re sponse to a ge neric sub sti tu tion in a Brit ish gen eral prac tice [Dowell et al. 1995] . Brennan and Lee [2004] re port the ex treme case of a pa tient be liev ing to be al ler gic to generic med i ca tions. Since ad verse ef fects in ge neric drugs are con tra dic tory to phar ma colog i cal find ings [Gleiter and Gundert-Remy 1994, Meredith 1996] , the ex pe ri ence of lo wer ef fi cacy or non-spe cific side ef fects of generic drugs in some pa tients ap pear to be a nocebo phe nom e non [Barsky et al. 2002] , an "ad verse pla cebo ef fect", so to speak.
A nocebo ef fect may oc cur as a re sult of any in ter ven tion, even of a ge neric sub sti tution. This ef fect is more likely if: -drugs are pri mar ily ad vo cated for their low price [Rietveld and Haaijer-Ruskamp 2002] , -in for ma tion on ge neric sub sti tu tion is erro ne ous, or -the phys i cal and sym bolic char ac ter is tics of the med i ca tion change [Barsky et al. 2002] .
Al though a "generics only" guide line is rea son able from a cost-ef fec tive ness per spective [Brennan and Lee 2004] , a too rigid generic sub sti tu tion may -at least in some instances -change the phy si cian-pa tient relationship for the worse, re awaken dis trust and lead to the ex pe ri ence of a lower ef fi cacy of ge neric drugs. Since a dif fer ent color or form of the ge neric sub sti tu tion also seemed to provoke skep ti cism to wards ge neric sub sti tu tion in our study, doc tors should also better prepare pa tients for such changes [Rietveld and Haaijer-Ruskamp 2002] and, thus, help to avoid much of the neg a tive feel ing gen er ated by the drug change it self [Dowell et al. 1995] . In an in ter ven tion study in Bar ce lona (Spain), in di vid ual pa tient ed u ca tion in pri mary care was also an ef fec tive strat egy for im prov ing ac cept abil ity of the sub sti tu tion of brandname drugs by ge neric drugs in re fill prescrip tions [Vallès 2003 ].
Conclusions
Proper in for ma tion of the pa tient may reduce the num ber of pa tients who are dis satis fied with the ge neric sub sti tu tion. Sub sti tution with out pro vi sion of in for ma tion may result in pa tient dis sat is fac tion, with drawal from care or shifts to more ex pen sive resources [Horn et al. 1996] .
Con sid er ing the re sults of our study, physi cians may adopt the fol low ing strat egy, at least in some pa tients, when pre scrib ing a generic drug: -ask the pa tient whether they are aware that there are al ter na tive drugs that are just as ef fi ca cious, -ask the pa tient about pre vi ous ex pe ri ence with ge neric sub sti tu tion, -em pha size with any feel ings ex pressed, -cor rect any mis in for ma tion, -make clear rec om men da tions.
Al though GPs are in an ideal po si tion to in form pa tients ad e quately about the equiv alence of brand and ge neric drugs, in some cases a sat is fac tory sub sti tu tion will per haps con sume an in ap pro pri ate amount of time with re gard to the costs saved be cause some pa tients' at ti tudes, or prej u dices, seem so nega tive and per sis tent that they will be difficult to rectify.
